Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.40 |
| ▸ | ADA | P00813 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PYGM | P11217 | 1/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466516 | 0.85 | ADORA2A (0.45) | ADORA2AADORA3ADAADORA1ADORA2B | |
| SCHEMBL6833725 | 0.84 | ADORA2A (0.46) | ADORA2AADORA3ADAADORA1ADORA2B | |
| SCHEMBL6833685 | 0.83 | ADORA2A (0.46) | ADORA2AADORA3ADAADORA1ADORA2B | |
| SCHEMBL474780 | 0.81 | ADORA2A (0.65) | ADORA2AADORA3ADAADORA1ADORA2B | |
| SCHEMBL873112 | 0.81 | ADORA2A (0.65) | ADORA2AADORA3ADAADORA1ADORA2B | |
| SCHEMBL13559231 | 0.80 | ADORA2A (0.66) | ADORA2AADORA3ADAADORA1ADORA2B | |
| SCHEMBL13559257 | 0.80 | ADORA2A (0.66) | ADORA2AADORA3ADAADORA1ADORA2B | |
| SCHEMBL17955705 | 0.80 | ADORA2A (0.66) | ADORA2AADORA3ADAADORA1ADORA2B | |
| SCHEMBL12149438 | 0.80 | ADORA2A (0.66) | ADORA2AADORA3ADAADORA1ADORA2B | |
| SCHEMBL13598741 | 0.79 | ADK (0.54) | ADORA2AADORA3ADORA1ADORA2BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA2A 174/4885ADORA3 170/4885ADA 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.